Younossi Z.M. Stepanova M. Younossi Y. et al.

Epidemiology of chronic liver diseases in the USA in the past three decades.

Gut. 69: 564Younossi Z.M. Koenig A.B. Abdelatif D. et al.

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Hepatology. 64: 73-84Asrani S.K. Devarbhavi H. Eaton J. et al.

Burden of liver diseases in the world.

J Hepatol. 70: 151-171Pierantonelli I. Svegliati-Baroni G.

Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH.

Transplantation. 103: e1-e13

Predicting the future burden of NAFLD and NASH.

J Hepatol. 69: 774-775

World Health Organization. Global hepatitis report, 2017 [Internet]. 2017. p. 1–83.

() ()

Hepatitis B and hepatocellular carcinoma.

Hepatology. 49: S56Lonardo A. Loria P. Adinolfi L.E. et al.

Hepatitis C and steatosis: a reappraisal.

J Viral Hepat. 13: 73-80Ceni E. Mello T. Galli A.

Pathogenesis of alcoholic liver disease: role of oxidative metabolism.

World J Gastroenterol. 20: 17756-17772Procopet B. Berzigotti A.

Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy.

Gastroenterol Rep. 5: 79-89

Liver fibrosis determination.

Gastroenterol Clin North Am. 48: 281-289Barr R.G. Wilson S.R. Rubens D. et al.

Update to the Society of Radiologists in Ultrasound Liver Elastography Consensus Statement.

Radiology. 296: 263-274Berg T. Sarrazin C. Hinrichsen H. et al.

Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?.

Hepatology. 39: 1456-1457Tian G. Kong D. Jiang T. et al.

Complications after percutaneous ultrasound-guided liver biopsy: a systematic review and meta-analysis of a population of more than 12,000 patients from 51 cohort studies.

J Ultrasound Med. 39: 1355-1365Chi H. Hansen B.E. Tang W.Y. et al.

Multiple biopsy passes and the risk of complications of percutaneous liver biopsy.

Eur J Gastroenterol Hepatol. 29: 36-41Ratziu V. Charlotte F. Heurtier A. et al.

Sampling variability of liver biopsy in nonalcoholic fatty liver disease.

Gastroenterology. 128: 1898-1906Sigrist R.M.S. Liau J. Kaffas A El et al.

Ultrasound elastography: review of techniques and clinical applications.

Theranostics. 7: 1303-1329Hu X. Qiu L. Liu D. et al.

Acoustic Radiation Force Impulse (ARFI) elastography for non-invasive evaluation of hepatic fibrosis in chronic hepatitis B and C patients: a systematic review and meta-analysis.

Med Ultrason. 19: 23-31Harding D.J. Perera M.T.P.R. Chen F. et al.

Portal vein thrombosis in cirrhosis: controversies and latest developments.

World J Gastroenterol. 21: 6769-6784Mantaka A. Augoustaki A. Kouroumalis E.A. et al.

Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges.

Ann Gastroenterol. 31: 315-329Sacerdoti D. Serianni G. Gaiani S. et al.

Thrombosis of the portal venous system.

J Ultrasound. 10: 12-21

Portal vein thrombosis.

J Clin Exp Hepatol. 5: 22-40Tarantino L. Ambrosino P. Di Minno M.N.D.

Contrast-enhanced ultrasound in differentiating malignant from benign portal vein thrombosis in hepatocellular carcinoma.

World J Gastroenterol. 21: 9457-9460Iranpour P. Lall C. Houshyar R. et al.

Altered Doppler flow patterns in cirrhosis patients: an overview [Internet]. Ultrasonography.

Korean Society of Ultrasound in Medicine, : 3-12Park H.S. Desser T.S. Jeffrey R.B. et al.

Doppler ultrasound in liver cirrhosis: correlation of hepatic artery and portal vein measurements with model for end-stage liver disease score.

J Ultrasound Med. 36: 725-730Horrow M.M. Huynh M.H.L. Callaghan M.M. et al.

Complications after liver transplant related to preexisting conditions: diagnosis, treatment, and prevention.

Radiographics. 40: 895-909

Ultrasound of diffuse liver disease including elastography.

Radiol Clin North Am. 57: 549-562Singal A.K. Ahmad M. Soloway R.D.

Duplex Doppler ultrasound examination of the portal venous system: an emerging novel technique for the estimation of portal vein pressure.

Dig Dis Sci. 55: 1230-1240Fitzmaurice C. Akinyemiju T.F. Al Lami F.H. et al.

Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016 a systematic analysis for the global burden of disease study global burden of disease cancer collaboration.

JAMA Oncol. 4: 1553-1568

The global epidemiology of hepatocellular carcinoma: present and future.

Clin Liver Dis. 15: 223-243Marrero J.A. Kulik L.M. Sirlin C.B. et al.

Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases.

Hepatology. 68: 723-750

Screening for hepatocellular carcinoma.

Gastroenterol Hepatol (N Y). 4: 201-208Chen J.G. Parkin D.M. Chen Q.G. et al.

Screening for liver cancer: results of a randomised controlled trial in Qidong, China.

J Med Screen. 10: 204-209Yeh Y.P. Hu T.H. Cho P.Y. et al.

Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan.

Hepatology. 59: 1840-1849Zhang B.-H. Yang B.-H. Tang Z.-Y.

Randomized controlled trial of screening for hepatocellular carcinoma.

J Cancer Res Clin Oncol. 130: 417-422Choi D.T. Kum H.C. Park S. et al.

Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis.

Clin Gastroenterol Hepatol. 17: 976-987.e4Mittal S. Kanwal F. Ying J. et al.

Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: a United States cohort.

J Hepatol. 65: 1148-1154Kokudo N. Takemura N. Hasegawa K. et al.

Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update.

Hepatol Res. 49: 1109-1113Omata M. Cheng A.L. Kokudo N. et al.

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Hepatol Int. 11: 317-370Park J.W. Lee J.S. Suh K.S. et al.

2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma.

Gut Liver. 13: 227-299Galle P.R. Forner A. Llovet J.M. et al.

EASL clinical practice guidelines: management of hepatocellular carcinoma.

J Hepatol. 69: 182-236

WHO Regional Office for Europe. Screening programmes: a short guide. Increase effectiveness, maximize benefits and minimize harm [Internet]. 2020.

() ()Yang B. Zhang B. Xu Y. et al.

Prospective study of early detection for primary liver cancer.

J Cancer Res Clin Oncol. 123: 357-360Bruix J. Sherman M. Llovet J.M. et al.

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference.

J Hepatol. 35: 421-430Cholankeril G. Patel R. Khurana S. et al.

Hepatocellular carcinoma in non-alcoholic steatohepatitis: current knowledge and implications for management.

World J Hepatol. 9: 533-543

American College of Radiology. Ultrasound LI-RADS v2017 [Internet].

() ()

American College of Radiology. ACR–AIUM–SPR–SRU practice parameter for the performance of an ultrasound examination of the abdomen and/or retroperitoneum [Internet].

() ()Choi H.H. Rodgers S.K. Fetzer D.T. et al.

Ultrasound Liver Imaging Reporting and Data System (US LI-RADS): an overview with technical and practical applications.

Acad Radiol. https://doi.org/10.1016/j.acra.2020.06.004Millet J.D. Kamaya A. Choi H.H. et al.

ACR ultrasound liver reporting and data system: multicenter assessment of clinical performance at one year.

J Am Coll Radiol. 16: 1656-1662Heimbach J.K. Kulik L.M. Finn R.S. et al.

AASLD guidelines for the treatment of hepatocellular carcinoma.

Hepatology. 67: 358-380